BlackRock, Inc. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Syros Pharmaceuticals, Inc. SYRS | BlackRock Inc. BLK | 152,431 2.400% | -270,796 (-63.98%) | Filing |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | BlackRock Inc. BLK | 423,227 6.800% | 90,671 (+27.26%) | Filing |
| 2021-02-01 08:23 am Purchase | 2020-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | BlackRock Inc. BLK | 332,556 7.300% | 46,215 (+16.14%) | Filing |